Iovance Biotherapeutics, Inc.
US ˙ NasdaqGM ˙ US4622601007

SecurityIOVA / Iovance Biotherapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership1,127,157 shares
Latest Disclosed Value $ 3,077,139
Barclays Plc ownership in IOVA / Iovance Biotherapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 1,127,157 shares of Iovance Biotherapeutics, Inc. (US:IOVA) valued at $3,077,139 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 936,687 shares of Iovance Biotherapeutics, Inc.. This represents a change in shares of 20.33% during the quarter. The current value of the position is $4,936,948 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (IOVA) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IOVA / Iovance Biotherapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 1,127,157 190,470 20.33 3,077 51.43 0.0007
2026-03-31 2025-09-30 13F/A-3 IOVANCE BIOTHERAPEUTICS COM 462260100 936,687 52,347 5.92 2,033 33.60 0.0004
2026-03-19 2025-09-30 13F/A-2 IOVANCE BIOTHERAPEUTICS COM 462260100 604,584 -279,756 5,677 0.0015
2025-11-12 2025-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 936,687 52,347 2,033 0.0004
2026-02-27 2025-06-30 13F/A-2 IOVANCE BIOTHERAPEUTICS COM 462260100 884,340 313,504 54.92 1,521 -19.95 0.0003
2025-08-14 2025-06-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 884,340 313,504 2 0.0003
2025-08-13 2025-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 884,340 313,504 2 0.0001
2026-03-17 2025-03-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 570,836 -46,967 -7.60 1,901 -58.43 0.0005
2025-05-15 2025-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 570,836 -46,967 2 0.0005
2026-03-19 2024-12-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 617,803 13,219 2.19 4,572 -19.48 0.0013
2025-02-13 2024-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 617,803 13,219 5 0.0013
2026-03-31 2024-09-30 13F/A-2 IOVANCE BIOTHERAPEUTICS COM 462260100 604,584 328,284 118.81 5,677 156.30 0.0015
2024-11-19 2024-09-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 604,584 328,284 6 0.0015
2024-11-15 2024-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 604,584 328,284 6 0.0015
2026-03-23 2024-06-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 276,300 20,947 8.20 2,216 -41.46 0.0007
2024-08-14 2024-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 276,300 20,947 2 0.0007
2026-03-24 2024-03-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 255,353 -580,822 -69.46 3,784 -44.34 0.0013
2024-05-15 2024-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 255,353 -580,822 4 0.0013
2026-03-25 2023-12-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 836,175 78,224 10.32 6,798 97.16 0.0025
2024-02-15 2023-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 836,175 78,224 7 0.0025
2026-03-26 2023-09-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 757,951 228,359 43.12 3,449 -7.51 0.0021
2023-11-07 2023-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 757,951 228,359 3 0.0021
2026-03-30 2023-06-30 13F/A-2 IOVANCE BIOTHERAPEUTICS COM 462260100 529,592 112,432 26.95 3,728 46.31 0.0024
2023-09-20 2023-06-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 529,592 112,432 4 0.0024
2023-08-03 2023-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 529,592 112,432 4 0.0024
2026-03-30 2023-03-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 417,160 -213,790 -33.88 2,549 -36.79 0.0012
2023-05-04 2023-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 417,160 -213,790 3 0.0012
2026-03-30 2022-12-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 630,950 240,344 61.53 4,032 7.72 0.0018
2023-02-13 2022-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 630,950 240,344 4 0.0018
2022-11-03 2022-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 390,606 347,191 799.70 3,742 681.21 0.0041
2022-08-12 2022-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 43,415 -29,849 -40.74 479 -60.77 0.0003
2022-05-16 2022-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 73,264 67,312 1,130.91 1,221 971.05 0.0010
2022-02-23 2021-12-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 5,952 -24,938 -80.73 114 -85.02 0.0000
2022-02-14 2021-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 5,952 -24,938 114 0.0000
2021-11-09 2021-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 30,890 -59,373 -65.78 761 -67.62 0.0003
2021-08-13 2021-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 90,263 21,869 31.98 2,350 8.49 0.0011
2021-05-13 2021-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 68,394 1,821 2.74 2,166 -29.90 0.0012
2021-02-11 2020-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 66,573 7,617 12.92 3,090 59.20 0.0016
2020-11-12 2020-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 58,956 -133,423 -69.35 1,941 -63.25 0.0012
2020-08-12 2020-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 192,379 70,563 57.93 5,281 44.76 0.0041
2020-05-13 2020-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 121,816 -87,865 -41.90 3,648 -37.15 0.0029
2020-02-10 2019-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 209,681 104,169 98.73 5,804 202.13 0.0032
2019-11-15 2019-09-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 105,512 30,578 40.81 1,921 4.52 0.0012
2019-11-14 2019-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 105,512 30,578 1,921 444.1374
2019-08-14 2019-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 74,934 18,906 33.74 1,838 244.19 0.0011
2019-05-15 2019-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 56,028 56,028 534 0.0004
2019-02-14 2018-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 0 -47,860 -100.00 0 -100.00
2018-11-14 2018-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 47,860 34,846 267.76 539 222.75 0.0004
2018-08-14 2018-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 13,014 -4,247 -24.60 167 -42.61 0.0001
2018-05-15 2018-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 17,261 -18,538 -51.78 291 1.75 0.0002
2018-02-14 2017-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 35,799 32,563 1,006.27 286 1,044.00 0.0002
2017-11-14 2017-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 3,236 3,196 7,990.00 25 0.0000
2017-08-14 2017-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 40 -1,417 -97.25 0 -100.00
2017-05-15 2017-03-31 13F LION BIOTECHNOLOGIES COM 53619R102 1,457 -1,212 -45.41 11 -38.89 0.0000
2017-02-14 2016-12-31 13F LION BIOTECHNOLOGIES COM 53619R102 2,669 -12,437 -82.33 18 -85.48 0.0000
2016-11-14 2016-09-30 13F LION BIOTECHNOLOGIES COM 53619R102 15,106 -61,821 -80.36 124 -80.10 0.0001
2016-08-12 2016-06-30 13F LION BIOTECHNOLOGIES COM 53619R102 76,927 76,632 25,976.95 623 62,200.00 0.0008
2016-05-16 2016-03-31 13F LION BIOTECHNOLOGIES COM 53619R102 295 -509 -63.31 1 -80.00 0.0000
2016-02-12 2015-12-31 13F LION BIOTECHNOLOGIES COM 53619R102 804 569 242.13 5 400.00 0.0000
2015-11-13 2015-09-30 13F LION BIOTECHNOLOGIES COM 53619R102 235 -626 -72.71 1 -87.50 0.0000
2015-08-14 2015-06-30 13F LION BIOTECHNOLOGIES COM 53619R102 861 861 8 0.0000
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-05-13 2020-03-31 13F IOVANCE BIOTHERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-10 2019-12-31 13F IOVANCE BIOTHERAPEUTICS OPT Put 4,000 111 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.